---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-26-000017"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2026-03-04T23:59:59+00:00"
generated_at: "2026-05-15T21:42:29.975957+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics reports Q4 net loss $23.5M, full-year net income $87.0M

## Summary
- Q4 2025 net loss $23.5M vs. $46.0M loss in Q4 2024; FY 2025 net income $87.0M vs. $187.4M loss in FY 2024.
- Cash and equivalents $287.4M as of Dec 31, 2025, expected to fund operations into first half of 2028.
- R&D expenses fell to $17.9M (Q4) and $129.6M (FY) due to transition of elritercept costs to Takeda.
- Charles Newton appointed to board effective March 9, 2026; Carl Gordon steps down. Esther Cho promoted to Chief Legal Officer.
- Phase 2 trial of rinvatercept for DMD expected to start in Q2 2026; ALS regulator engagement planned for H2 2026.

## SEC filing metadata
- accession: 0001664710-26-000017
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2026-03-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000017/0001664710-26-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471026000017/kros-20260304.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-26-000017
- JSON: https://secwatch.observer/filing/0001664710-26-000017.json
- Plain text: https://secwatch.observer/filing/0001664710-26-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.